US 11845965
Regulation of gene expression using engineered nucleases
granted A61KA61K2035/124A61K35/28
Quick answer
US patent 11845965 (Regulation of gene expression using engineered nucleases) held by Sangamo Therapeutics, Inc. expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Sangamo Therapeutics, Inc.
- Grant date
- Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61K, A61K2035/124, A61K35/28, A61K38/00, A61P